Stockscreener 앱 받기
6.76
1.46%
-0.10
시간 외 거래:
6.79
0.03
+0.44%
전일 마감가:
$6.86
열려 있는:
$6.7
하루 거래량:
8.65M
Relative Volume:
2.01
시가총액:
$1.42B
수익:
$557.51M
순이익/손실:
$-35.71M
주가수익비율:
-37.56
EPS:
-0.18
순현금흐름:
$15.50M
1주 성능:
-6.63%
1개월 성능:
-5.45%
6개월 성능:
-24.30%
1년 성능:
-8.03%
1일 변동 폭
$6.51
$6.895
1주일 범위
$6.51
$7.47
52주 변동 폭
$6.00
$11.31
바이오크리스트 Stock (BCRX) Company Profile
명칭
Biocryst Pharmaceuticals Inc
전화
919-859-1302
주소
4505 EMPEROR BOULEVARD, DURHAM, NC
BCRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
6.76 | 1.44B | 557.51M | -35.71M | 15.50M | -0.18 |
|
ZTS
Zoetis Inc
|
124.46 | 63.97B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.56 | 42.40B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.32 | 41.77B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.46 | 23.54B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
437.33 | 18.89B | 3.08B | 1.24B | 1.07B | 25.61 |
바이오크리스트 Stock (BCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-15 | 재개 | TD Cowen | Buy |
| 2025-10-01 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-02-25 | 개시 | Wedbush | Outperform |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-09-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-13 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-02-22 | 업그레이드 | Needham | Hold → Buy |
| 2022-11-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-08-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-04-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-04-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-10 | 개시 | Oppenheimer | Outperform |
| 2021-08-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2020-09-29 | 재개 | JP Morgan | Overweight |
| 2020-06-17 | 개시 | BTIG Research | Neutral |
| 2020-05-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-15 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | 재개 | Piper Jaffray | Overweight |
| 2018-08-08 | 재개 | JP Morgan | Overweight |
| 2018-07-17 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | 개시 | Seaport Global Securities | Neutral |
| 2018-01-02 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | 개시 | Barclays | Equal Weight |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-09-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-02-16 | 개시 | Ladenburg Thalmann | Buy |
| 2016-08-12 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | FBR Capital | Outperform |
| 2016-02-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2016-02-09 | 다운그레이드 | Needham | Buy → Hold |
모두보기
바이오크리스트 주식(BCRX)의 최신 뉴스
Barclays Lowers Price Target on BioCryst Pharma (BCRX) to $9 wit - GuruFocus
BioCryst Pharmaceuticals (NASDAQ:BCRX) Releases Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q3 2025 Earnings Call Transcript - Insider Monkey
Needham's Analyst Update: BioCryst Pharma (BCRX) Price Target Re - GuruFocus
Hussman Strategic Advisors Inc. Has $1.88 Million Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
What technical models suggest about BioCryst Pharmaceuticals Inc.’s comebackQuarterly Profit Review & Stock Portfolio Risk Control - newser.com
BioCryst Pharmaceuticals (BCRX) Is Up After Raising ORLADEYO Outlook and Returning to Profitability – What’s Changed - Yahoo Finance
BioCryst Pharmaceuticals Inc.’s volatility index tracking explained2025 Price Targets & Free Real-Time Volume Trigger Notifications - newser.com
T-cell Lymphoma Market Report with Detailed Study Analysis - openPR.com
BioCryst: Q3 Earnings Snapshot - CT Insider
BioCryst Pharmaceuticals (BCRX): Forecasts Call for 56.3% Annual Earnings Growth Heading Into Earnings Season - Yahoo Finance
BioCryst Pharmaceuticals Inc (BCRX) Q3 2025 Earnings Call Highlights: Strong Orladeo Growth and ... - Yahoo Finance
BioCryst Pharmaceuticals, Inc. Appoints Ron Dullinger as Chief Commercial Officer, Effective January 1, 2026 - MarketScreener
BioCryst Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2025 - MarketScreener
BioCryst Pharmaceuticals Inc reports results for the quarter ended September 30Earnings Summary - TradingView
BioCryst (BCRX) Q3 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: BioCryst Q3 2025 earnings beat estimates, stock dips - Investing.com
BioCryst (BCRX) Revenue Falls Short but Strategic Moves Drive Fu - GuruFocus
BioCryst Pharmaceuticals (BCRX) Reports Strong Q3 Earnings, Rais - GuruFocus
BioCryst Reports Q3 2025 Financial Growth and Strategy - TipRanks
BioCryst Pharmaceuticals Inc (BCRX) Q3 2025 Earnings: EPS of $0. - GuruFocus
BioCryst (BCRX) Adjusts 2025 Financial Projections for ORLADEYO - GuruFocus
Earnings Flash (BCRX) BioCryst Pharmaceuticals, Inc. Reports Q3 Revenue $159.4M, vs. FactSet Est of $163.0M - MarketScreener
Earnings Flash (BCRX) BioCryst Pharmaceuticals, Inc. Posts Q3 Adjusted EPS $0.16 per Share, vs. FactSet Est of $0.07 - MarketScreener
BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update - Bluefield Daily Telegraph
Will BioCryst Pharmaceuticals Inc. stock maintain growth storyQuarterly Growth Report & AI Powered Market Entry Ideas - newser.com
When is the best time to exit BioCryst Pharmaceuticals Inc.July 2025 Short Interest & AI Driven Stock Reports - newser.com
Why BioCryst Pharmaceuticals Inc. stock could benefit from AI revolution2025 Top Decliners & Consistent Return Investment Signals - newser.com
Is BioCryst Pharmaceuticals Inc. stock bottoming out2025 Volatility Report & Technical Entry and Exit Tips - newser.com
Will BioCryst Pharmaceuticals Inc. stock attract ESG investors2025 Technical Patterns & Precise Buy Zone Identification - newser.com
Why retail investors pile into BioCryst Pharmaceuticals Inc. stock2025 Dividend Review & Technical Entry and Exit Alerts - newser.com
Is BioCryst Pharmaceuticals Inc. stock ready for a breakoutWeekly Earnings Recap & Weekly Return Optimization Alerts - newser.com
Y Intercept Hong Kong Ltd Increases Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Promising Biotech Stocks To Follow TodayOctober 14th - MarketBeat
# BioCryst’s SWOT analysis: stock positioned for growth amid HAE market expansion - Investing.com
BioCryst Pharmaceuticals (BCRX) Price Target Increased by 19.59% to 21.51 - Nasdaq
바이오크리스트 (BCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.60%
0.45%
자본화:
|
볼륨(24시간):